LAST UPDATED
October 5, 2023
Clinicaltrials.gov ID
EudraCT ID
A Multicenter, Open-label, Randomized Phase 3 Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients With Chronic Hepatitis Delta
The primary objective of this study is to evaluate the efficacy of bulevirtide for treatment of chronic hepatitis delta (CHD) in comparison to delayed treatment.
View MoreAge
18 Years - 65 Years
Sex
All
Healthy Volunteers
No
Medical Condition
Chronic Hepatitis Delta
Gender
N/A
Date
April 2019 - November 2020
Study Type
Interventional
Study Phase
Phase 3
Product
Bulevirtide
New York, New York, United States, 10016
New York, New York, United States, 10021
Essen, Germany
Frankfurt am Main, Germany
Hamburg, Germany
Hannover, Germany
Heidelberg, Germany
Milan, Italy
Modena, Italy
Pisa, Italy
Chelyabinsk, Russian Federation
Krasnodar, Russian Federation
Moscow, Russian Federation
Moscow, Russian Federation
Moscow, Russian Federation
Moscow, Russian Federation
Samara, Russian Federation
Stavropol', Russian Federation
Stockholm, Sweden
Share Trial